HomeWebcastBPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020
Online CLE BPCIA Patent CLE

BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020

Live Webcast Date: Thursday, February 06, 2020 from 3:00 pm to 5:00 pm (ET)
Intellectual Property CLE & CPELive Webcast
Registration & Pricing Options
Add to Calendar 02/06/2020 3:00 pm 02/06/2020 5:00 pm America/New_York The Knowledge Group Webinar: BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020 If you haven’t registered for this event please click here:https://www.theknowledgegroup.org/checkout/?add-to-cart=72234\r\n Since the beginning of 2019, the number of biosimilar litigation - particularly those concerning the Biologics Price Competition and Innovation Act (BPCIA) “patent dance” - has drastically increased. One of the notable BCPIA cases that are being closely watched, is Amgen’s legal battle with Novartis’ Sandoz arm over the Enbrel patent, in which the former intends to hold commercial exclusivity for Enbrel until 2029. The legal precedents established in this dispute are expected to impact the biosimilar market as well as the pending and future biosimilar patent lawsuits. \n \nWith the changing biosimilar landscape and stiffer competition in the backdrop, counsel to drug companies should keep an eye out for these lawsuits and other legal developments to devise effective patent management and litigation strategies. \n \nJoin a panel of key thought leaders and professionals assembled by The Knowledge Group as they provide the audience with an in-depth analysis of the recent biosimilar litigation trends relating to the BPCIA patent dance. Speakers will also offer the best patent management and litigation practices in light of the recent developments. \n \nThis LIVE Webcast will discuss the following key provisions: \n \n \n The BPCIA Patent Dance – Statistics and Recent Trends \n Notable Cases and Court Decisions \n Best Patent Management Practices \n Effective Litigation Strategies \n Outlook \n https://www.theknowledgegroup.org/webcasts/bpcia-patent-dance/

Online CLE BPCIA Patent

Join us for this Knowledge Group Online CLE BPCIA Patent Webinar. Since the beginning of 2019, the number of biosimilar litigation - particularly those concerning the Biologics Price Competition and Innovation Act (BPCIA) “patent dance” - has drastically increased. One of the notable BCPIA cases that are being closely watched, is Amgen’s legal battle with Novartis’ Sandoz arm over the Enbrel patent, in which the former intends to hold commercial exclusivity for Enbrel until 2029. The legal precedents established in this dispute are expected to impact the biosimilar market as well as the pending and future biosimilar patent lawsuits.

With the changing biosimilar landscape and stiffer competition in the backdrop, counsel to drug companies should keep an eye out for these lawsuits and other legal developments to devise effective patent management and litigation strategies.

Join a panel of key thought leaders and professionals assembled by The Knowledge Group as they provide the audience with an in-depth analysis of the recent biosimilar litigation trends relating to the BPCIA patent dance. Speakers will also offer the best patent management and litigation practices in light of the recent developments.

This LIVE Webcast will discuss the following key provisions:

  • The BPCIA Patent Dance – Statistics and Recent Trends
  • Notable Cases and Court Decisions
  • Best Patent Management Practices
  • Effective Litigation Strategies
  • Outlook

Agenda

SEGMENT 1:
Sean Sheridan, Principal
Charles River Associates

SEGMENT 2:
Eberle Schultz, Counsel
O'Melveny & Myers LLP

Who Should Attend

  • Biotech and Pharmaceutical Companies
  • Patent Lawyers and Consultants
  • Patent Litigators
  • In-house Counsel
  • Top Level Management

Online CLE BPCIA Patent

SEGMENT 1:
Sean Sheridan, Principal
Charles River Associates

SEGMENT 2:
Eberle Schultz, Counsel
O'Melveny & Myers LLP

Online CLE BPCIA Patent

Online CLE BPCIA Patent

Sean SheridanPrincipalCharles River Associates

Online CLE BPCIA Patent

Eberle SchultzCounselO'Melveny & Myers LLP


Click Here to Read Additional Material

Online CLE BPCIA Patent

Course Level:
   Intermediate

Advance Preparation:
   Print and review course materials

Method Of Presentation:
   Live Webcast

Prerequisite:
   General knowledge of biosimilar patent laws

Course Code:
   147359

NY Category of CLE Credit:
   Areas of Professional Practice

Total Credits:
    2.0 CLE

No Access

You are not logged in. Please or register to the event to gain access to the materials and login instructions.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

About the Knowledge Group

The Knowledge Group

The Knowledge Group has been a leading global provider of Continuing Education (CLE, CPE) for over 13 Years. We produce over 450 LIVE webcasts annually and have a catalog of over 4,000 on-demand courses.

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.

Website: https://www.omm.com/

Ultimate Value Annual Program

Bring a colleague for only $149, a savings of $50 per additional attendee.

  • Unlimited Access to Live & Recorded Webcasts
  • Instant Access to Course Materials
  • And More!

$199